BridgePoint Medical Inc. raised $1 million from the sale of debt and stock warrants, according to documents filed with the federal Securities and Exchange Commission.
The company, based in Plymouth, Minn., is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
Last year, European regulators approved BridgePoint’s Chronic Total Occlusion Crossing system comprised of the CrossBoss CTO crossing catheter and the Stingray CTO re-entry system. The company is currently conducting clinical trials in the U.S.
Its backers include Foundation Medical Partners, Polaris Ventures, New Enterprise Associates, and Mike Berman, a prominent local medical device entrepreneur.
Berman did not respond to an e-mail requesting comment.